Lytgobi (Futibatinib)
- Drug Name: Lytgobi
- API: Futibatinib
- Dosage Forms and Strengths: Tablets, 4 mg
- Manufactured by: Taiho Oncology Inc.
LYTGOBI is a kinase inhibitor approved for the treatment of adult patients with previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma characterized by fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. This indication is granted under accelerated approval based on overall response rate and response duration. Continued approval may be subject to verification and description of clinical benefit in confirmatory trials.
Dosage and Administration
- Confirm the presence of an FGFR2 gene fusion or other rearrangement before initiating LYTGOBI treatment.
- The recommended dosage is 20 mg taken orally (five 4 mg tablets) once daily until disease progression or unacceptable toxicity occurs.
- Swallow the tablet whole, with or without food.
- Ocular Toxicity: LYTGOBI may lead to retinal pigment epithelial detachment (RPED). It is essential to conduct a comprehensive ophthalmological examination, including optical coherence tomography (OCT), before initiating therapy, every 2 months for the first 6 months, and every 3 months thereafter. Urgent evaluation is warranted at any time if visual symptoms arise.
- Hyperphosphatemia and Soft Tissue Mineralization: Elevated phosphate levels can result in hyperphosphatemia, leading to soft tissue mineralization, calcinosis, nonuremic calciphylaxis, and vascular calcification. Monitoring for hyperphosphatemia is crucial, and treatment may involve withholding, dose reduction, or permanent discontinuation, depending on the duration and severity of hyperphosphatemia.
- Embryo-Fetal Toxicity: LYTGOBI carries a risk of causing harm to a developing fetus. Patients of reproductive potential should be informed about the potential fetal risk and advised to use effective contraception.
If you are considering the import of Lytgobi (Futibatinib) to India, please be aware that Lytgobi can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:
Required Documentation for Import:
- A valid prescription from a qualified medical practitioner.
- Diagnostic reports of the patient.
- Government-issued identification proof for the patient, as recognized by the Government of India.
Order Confirmation Process:
The order for Lytgobi will be confirmed upon the receipt of the following documents:
- A valid prescription from a qualified doctor.
- An import permit, if applicable.
Availability of Lytgobi in India:
Lytgobi (Futibatinib) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.
Lytgobi can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.
IPN (Indian Pharma Network) is dedicated to facilitating the supply of Lytgobi (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.
For inquiries regarding the price of Lytgobi in India and to initiate the ordering process, please reach out to us through the following contact details:
Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.
Indian Pharma Network is proficient in sourcing Lytgobi (Futibatinib) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.
What is Lytgobi used for?
LYTGOBI is a prescription medicine that is used to treat adults with bile duct cancer (intrahepatic cholangiocarcinoma) that has spread or cannot be removed by surgery, who have already received a previous treatment, and whose tumor has a certain type of abnormal “FGFR2” gene.
What is Futibatinib used for?
Futibatinib is used to treat intrahepatic cholangiocarcinoma (bile duct cancer within the liver) that has spread or cannot be removed by surgery. It is used in patients who have already tried cancer treatment before and have a certain type of abnormal FGFR2 gene in their cancer.
Is Lytgobi approved by the FDA?
On September 30, 2022, the FDA granted accelerated approval to futibatinib, brand name Lytgobi for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements.
Who manufactures Futibatinib?
Taiho Pharmaceutical
What are the side effects of Futibatinib?
The most common (≥20%) adverse reactionswere nail toxicity, musculoskeletal pain, constipation, diarrhea, fatigue, dry mouth, alopecia, stomatitis, abdominal pain, dry skin, arthralgia, dysgeusia, dry eye, nausea, decreased appetite, urinary tract infection, palmar-plantar .
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.